Myocardial metastasis from renal cell carcinoma treated with sorafenib
Tokuyama, Y.; Iwamura, M.; Fujita, T.; Sugita, A.; Maeyama, R.; Bessho, H.; Ishikawa, W.; Tabata, K.-i.; Yoshida, K.; Baba, S.
Hinyokika Kiyo. Acta Urologica Japonica 57(10): 555-558
2011
ISSN/ISBN: 0018-1994 PMID: 22089153 Document Number: 648719
We present a case of myocardial metastasis from renal cell carcinoma (RCC) during the treatment with sorafenib. A 63-year-old male, who had undergone right radical nephrectomy, received interferon-alpha (IFN), interleukin (IL-2) and 5-flurouracil (5-FU) for the treatment of lung and pleural metastases. However, since this metastasis showed progressive disease, we administered sorafenib. Nine months after the introduction of sorafenib, he complained of dyspnea. Chest computed tomography and cardiac ultrasonography revealed a low density mass at the cardiac muscle of the left cardiac ventricle, suggesting myocardial metastasis of RCC. Molecular targeted therapy achieved a longer survival in advanced RCC patients in comparison with the immunotherapy using cytokines. Therefore, in metastasis evaluation, some organs which have been regarded as rare sites should be carefully evaluated.